Northern Trust Corp Puma Biotechnology, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 317,739 shares of PBYI stock, worth $873,782. This represents 0.0% of its overall portfolio holdings.

Number of Shares
317,739
Previous 105,058 202.44%
Holding current value
$873,782
Previous $342,000 136.84%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$2.25 - $4.03 $478,532 - $857,104
212,681 Added 202.44%
317,739 $810,000
Q2 2024

Aug 14, 2024
BUY
$2.92 - $5.83 $62,841 - $125,467
21,521 Added 25.76%
105,058 $342,000
Q1 2024

May 14, 2024
SELL
$4.29 - $7.4 $969 - $1,672
-226 Reduced 0.27%
83,537 $442,000
Q4 2023

Feb 13, 2024
BUY
$2.23 - $4.49 $31,913 - $64,256
14,311 Added 20.61%
83,763 $362,000
Q3 2023

Nov 13, 2023
SELL
$2.63 - $4.09 $376 - $584
-143 Reduced 0.21%
69,452 $182,000
Q2 2023

Aug 11, 2023
SELL
$2.6 - $3.58 $639 - $880
-246 Reduced 0.35%
69,595 $245,000
Q1 2023

May 15, 2023
BUY
$2.21 - $4.82 $7,525 - $16,412
3,405 Added 5.13%
69,841 $215,000
Q4 2022

Feb 13, 2023
SELL
$2.12 - $5.08 $5,331 - $12,776
-2,515 Reduced 3.65%
66,436 $281,000
Q3 2022

Nov 14, 2022
SELL
$2.27 - $3.84 $79 - $134
-35 Reduced 0.05%
68,951 $163,000
Q2 2022

Aug 12, 2022
SELL
$1.64 - $3.3 $352,841 - $709,985
-215,147 Reduced 75.72%
68,986 $197,000
Q1 2022

May 13, 2022
SELL
$2.13 - $3.24 $44,796 - $68,140
-21,031 Reduced 6.89%
284,133 $818,000
Q4 2021

Feb 08, 2022
SELL
$2.85 - $6.58 $127,218 - $293,718
-44,638 Reduced 12.76%
305,164 $927,000
Q3 2021

Nov 15, 2021
BUY
$6.63 - $9.39 $30,438 - $43,109
4,591 Added 1.33%
349,802 $2.45 Million
Q2 2021

Aug 13, 2021
SELL
$8.98 - $11.6 $3,592 - $4,640
-400 Reduced 0.12%
345,211 $3.17 Million
Q1 2021

May 12, 2021
SELL
$9.38 - $13.63 $196,323 - $285,275
-20,930 Reduced 5.71%
345,611 $3.36 Million
Q4 2020

Feb 11, 2021
SELL
$7.78 - $12.13 $46,143 - $71,943
-5,931 Reduced 1.59%
366,541 $3.76 Million
Q3 2020

Nov 16, 2020
SELL
$9.5 - $11.14 $204,573 - $239,888
-21,534 Reduced 5.47%
372,472 $3.76 Million
Q2 2020

Aug 14, 2020
BUY
$7.01 - $13.24 $98,055 - $185,201
13,988 Added 3.68%
394,006 $4.11 Million
Q1 2020

May 14, 2020
BUY
$6.28 - $14.57 $41,303 - $95,826
6,577 Added 1.76%
380,018 $3.21 Million
Q4 2019

Feb 14, 2020
SELL
$6.5 - $10.73 $91,468 - $150,992
-14,072 Reduced 3.63%
373,441 $3.27 Million
Q3 2019

Nov 13, 2019
BUY
$8.75 - $12.85 $272,623 - $400,367
31,157 Added 8.74%
387,513 $4.17 Million
Q2 2019

Aug 13, 2019
BUY
$12.3 - $35.76 $18,167 - $52,817
1,477 Added 0.42%
356,356 $4.53 Million
Q1 2019

May 13, 2019
BUY
$20.77 - $42.37 $41,415 - $84,485
1,994 Added 0.57%
354,879 $13.8 Million
Q4 2018

Feb 12, 2019
SELL
$20.07 - $46.7 $62,658 - $145,797
-3,122 Reduced 0.88%
352,885 $7.18 Million
Q3 2018

Nov 14, 2018
BUY
$41.2 - $59.85 $323,708 - $470,241
7,857 Added 2.26%
356,007 $16.3 Million
Q2 2018

Sep 18, 2018
SELL
$48.3 - $68.25 $113,311 - $160,114
-2,346 Reduced 0.67%
348,150 $20.6 Million
Q2 2018

Aug 14, 2018
BUY
$48.3 - $68.25 $429,000 - $606,196
8,882 Added 2.6%
350,496 $20.7 Million
Q1 2018

May 09, 2018
BUY
$59.7 - $99.25 $291,753 - $485,034
4,887 Added 1.45%
341,614 $23.2 Million
Q4 2017

Feb 14, 2018
SELL
$93.85 - $132.45 $857,132 - $1.21 Million
-9,133 Reduced 2.64%
336,727 $33.3 Million
Q3 2017

Nov 13, 2017
BUY
$72.0 - $119.75 $24.9 Million - $41.4 Million
345,860
345,860 $41.4 Million

Others Institutions Holding PBYI

# of Institutions
101
Shares Held
29M
Call Options Held
50.6K
Put Options Held
16.3K
View Full List

About PUMA BIOTECHNOLOGY, INC.

PBYI Quotes by TradingView
  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $125M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email